Clinical Trials
60 trialsMatch Mel
Melanoma Institute Australia
TAPUR
American Society of Clinical Oncology
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
MegaMOST
Centre Leon Berard
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Neo Combi
Melanoma Institute Australia
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
PLGG - MEKTRIC
University Hospital, Strasbourg, France
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
MATRIX-Rare
Oslo University Hospital
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
NETCAM
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
FINPROVE
Helsinki University Central Hospital
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
plexifpc
Region Skane
ANAPLAST-NEO
Saint Petersburg State University, Russia
Swecranio
Skane University Hospital
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Stanford University
DRUP
The Netherlands Cancer Institute
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Seoul St. Mary's Hospital
I-FIRST
Olivia Newton-John Cancer Research Institute
NEO-ATACT
Leiden University Medical Center
TraMel-WT
Universitair Ziekenhuis Brussel
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Neo Trio
Melanoma Institute Australia
MEMBRAINS
Herlev Hospital
ERRITI
University Hospital, Essen
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
University Health Network, Toronto
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Massachusetts General Hospital
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Vanderbilt-Ingram Cancer Center
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
National University Hospital, Singapore
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
BOTTOM
University Hospital, Essen
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
University of California, San Francisco
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
University of California, San Francisco